Jump to content

Genentech/Roche's Avastin Will Account for More Than 50% of

Recommended Posts

Genentech/Roche's Avastin Will Account for More Than 50% of the Non-Small-Cell Lung Cancer Drug Market in 2014

http://www.prnewswire.com/cgi-bin/stori ... 144&EDATE=

Generics Erosion Threatens Three Major Drugs in the Lung Cancer Market,

According to a New Study from Decision Resources

Waltham, Mass., June 7 /PRNewswire/ -- Decision Resources, Inc., one of

the world's leading research and advisory firms focusing on pharmaceutical and

health care issues, finds that Genentech/Roche's Avastin will account for more

than 50% of the non-small-cell lung cancer drug market in 2014. "Novel, targeted biological therapies, such as the anti-angiogenic

monoclonal antibody bevacizumab (Genentech/Roche's Avastin), will further

expand treatment options for advanced disease," said Mohammed Muhsin, analyst

at Decision Resources, Inc. "Avastin will be launched in 2006 and will be the

main driver of the non-small-cell lung cancer market from 2009 to 2014."

The new Pharmacor study entitled Non-Small-Cell Lung Cancer also finds

that generics erosion will threaten three major drugs in the non-small-cell

lung cancer drug market. The recent patent expiry of carboplatin in the United

States and patient expiries of Sanofi-Aventis's docetaxel and Eli Lilly's

gemcitabine in the United States and other markets will constrain the market

value of these agents.

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.